The coming of age of tumour immunotherapy

Immunology and Cell Biology

Volumn 77, Issue 2, 1999, Pages 180-185

  Ada, Gordon ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Chimeric vectors; Cytotoxic T lymphocytes; Dendritic cells; DNA; Immunotherapy; Neoplasia; Tumour antigens; Vaccination

Indexed keywords

TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD TRANSFUSION; CELL KILLING; CHIMERA; COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; TUMOR IMMUNITY; VACCINATION;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA;

EID: 0032920776     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1999.00803.x     Document Type: Conference Paper

References (26)

1. Ada GL. Prospects for HIV vaccines. J. AIDS 1988; 1: 295-303.
2. Burnet FM. Cancer: A biological approach. BMJ 1957; 1: 779-86.
3. Thomas L. Quoted in Fenner F. Frank Macfarlane Burnet, 1899-1985. Hist. Rec. Aust. Sci. 1987; 7: 39-77.
4. Burnet FM. Immunological aspects of malignant disease. Lancet 1967; 1: 1171-1174.
5. Advances in global measles control and elimination. Summary of the 1997 international meeting. Morb. Mortal. Wkly Rep. 1998; 24: 1-23.
6. Ada G, Ramsay A. Vaccines, Vaccination and the Immune Response. Philadelphia: Lippincott-Raven, 1997.
7. Nossal GJV. Some landmarks in Australian immunology. Immunol. Cell Biol. 1991; 69: 327-36.
8. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: Opportunities for new therapeutic approaches. Nature Med. 1997; 3: 505-9.
9. Woodruff M. Interaction of cancer and host [The Walter Hubert Lecture]. Br. J. Cancer 1982; 46: 313-22.
10. Ellem KAO, Schmidt CW, Li C-L et al. The labyrinthine ways of cancer immunotherapy: T cell, tumour cell encounter: 'How do I lose thee? Let me count the ways'. Adv. Cancer Res. 1998; 75: 204-42.
11. Browning J, Horner JW, Pettoello-Mantovani M et al. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc. Natl Acad. Sci. 1988; 94: 14 637-41.
12. Apostolopoulos V, Osinski C, McKenzie IFC. MUC1 cross-reactive Galα (1,3) Gal antibodies in humans switch immune response from cellular to humoral. Nature Med. 1988; 4: 315-20.
13. Apostolopoulos V, Pietersz G, Gordon S et al. Aldehyde-mannan antigen complexes target the MHC class I pathway. J. Immunol. 1999; in press.
14. Ada GL. The immunology of vaccination. In: Plotkin SE, Orenstein W (eds). Vaccines, 3rd edn. Philadelphia: W. Saunders and Co., 1999; in press.
15. Graham BS, Matthews TJ, Belshe RB et al. Augmentation of human immunodeficiency virus type-1 neutralising antibody by priming with gp160 recombinant vaccinia virus and boosting with rpg160 in vaccinia-naive adults. J. Infect. Dis. 1993; 167: 533-7.
16. Leong KH, Ramsay AJ, Morin MJ et al. Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowlpox virus. In: Brown F, Chanock R, Ginsberg H, Norrby E (eds). Vaccines 95. New York: Cold Spring Harbor Laboratory Press, 1995; 327-31.
17. Ramsay AJ, Leong KH, Ramshaw IA. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunisation with DNA and viral vectors. Immunol. Cell Biol. 1997; 75: 382-8.
18. Richmond JFL, Mustafa F, Lu S et al. Screening of HIV-1 env glycoproteins for the ability to raise neutralising antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 1997; 230: 265-74.
19. Hanke T, Blanchard TJ, Schneider J et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1988; 16: 439-45.
20. Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 1988; 4: 397-402.
21. Kent SJ, Zhao A, Best SJ et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type-1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 1998; 72: 10 180-8.
22. Robinson HL, Ginsburgh HS, Davis HL et al. The Scientific Future of DNA for Immunization. Washington: American Academy of Microbiology, 1997; 1-31.
23. Darji A, Guzman CA, Gerstel B et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997; 91: 765-75.
24. Altman JD, Moss PAH, Goulder PJR et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-6.
25. Walker CM, Erikson AL, Hseuh FC, Levy J. Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a non-cytotoxic mechanism. J. Virol. 1991; 65: 5921-7.
26. Pardoll D. Maturation of cancer vaccines. A meeting report on 'Cancer vaccines 1996' sponsored by the Cancer Research Institute, held 7-9 October 1996. Biochim. Biophys. Acta 1997; 1332: R33-6.